375 related articles for article (PubMed ID: 9153428)
41. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
Hong JH
Hiroshima J Med Sci; 1989 Dec; 38(4):197-207. PubMed ID: 2561562
[TBL] [Abstract][Full Text] [Related]
42. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells.
Takano H; Ise T; Nomoto M; Kato K; Murakami T; Ohmori H; Imamura T; Nagatani G; Okamoto T; Ohta R; Furukawa M; Shibao K; Izumi H; Kuwano M; Kohno K
Anticancer Drug Des; 1999 Apr; 14(2):87-92. PubMed ID: 10405635
[TBL] [Abstract][Full Text] [Related]
43. Genomic organization and mapping of transcription and translation products of the NADL-2 strain of porcine parvovirus.
Bergeron J; Menezes J; Tijssen P
Virology; 1993 Nov; 197(1):86-98. PubMed ID: 8212598
[TBL] [Abstract][Full Text] [Related]
44. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
45. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
Nitiss JL; Vilalta PM; Wu H; McMahon J
Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059
[TBL] [Abstract][Full Text] [Related]
46. Novel transmembrane GTPase of non-small cell lung cancer identified by mRNA differential display.
Chung JG; Yeh KT; Wu SL; Hsu NY; Chen GW; Yeh YW; Ho HC
Cancer Res; 2001 Dec; 61(24):8873-9. PubMed ID: 11751411
[TBL] [Abstract][Full Text] [Related]
47. Nucleotide sequence analysis of the CDNA for rat DNA topoisomerase II.
Park SH; Yoon JH; Kwon YD; Park SD
Biochem Biophys Res Commun; 1993 Jun; 193(2):787-93. PubMed ID: 8390253
[TBL] [Abstract][Full Text] [Related]
48. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer.
Takahashi T; D'Amico D; Chiba I; Buchhagen DL; Minna JD
J Clin Invest; 1990 Jul; 86(1):363-9. PubMed ID: 2164047
[TBL] [Abstract][Full Text] [Related]
49. A comparison of genomic structures and expression patterns of two closely related flanking genes in a critical lung cancer region at 3p21.3.
Timmer T; Terpstra P; van den Berg A; Veldhuis PM; Ter Elst A; Voutsinas G; Hulsbeek MM; Draaijers TG; Looman MW; Kok K; Naylor SL; Buys CH
Eur J Hum Genet; 1999; 7(4):478-86. PubMed ID: 10352938
[TBL] [Abstract][Full Text] [Related]
50. Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.
Lok CN; Lang AJ; Mirski SE; Cole SP
Biochem J; 2002 Dec; 368(Pt 3):741-51. PubMed ID: 12197834
[TBL] [Abstract][Full Text] [Related]
51. Differential expression of nuclear envelope lamins A and C in human lung cancer cell lines.
Kaufmann SH; Mabry M; Jasti R; Shaper JH
Cancer Res; 1991 Jan; 51(2):581-6. PubMed ID: 1985776
[TBL] [Abstract][Full Text] [Related]
52. Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines.
Meazza R; Verdiani S; Biassoni R; Coppolecchia M; Gaggero A; Orengo AM; Colombo MP; Azzarone B; Ferrini S
Oncogene; 1996 May; 12(10):2187-92. PubMed ID: 8668345
[TBL] [Abstract][Full Text] [Related]
53. Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells.
Deffie AM; Bosman DJ; Goldenberg GJ
Cancer Res; 1989 Dec; 49(24 Pt 1):6879-82. PubMed ID: 2555055
[TBL] [Abstract][Full Text] [Related]
54. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.
Smith PJ; Souès S; Gottlieb T; Falk SJ; Watson JV; Osborne RJ; Bleehen NM
Br J Cancer; 1994 Nov; 70(5):914-21. PubMed ID: 7947097
[TBL] [Abstract][Full Text] [Related]
55. Aberrant upregulation of a novel integrin alpha subunit gene at 3p21.3 in small cell lung cancer.
Hibi K; Yamakawa K; Ueda R; Horio Y; Murata Y; Tamari M; Uchida K; Takahashi T; Nakamura Y; Takahashi T
Oncogene; 1994 Feb; 9(2):611-9. PubMed ID: 8290272
[TBL] [Abstract][Full Text] [Related]
56. Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants.
Liu SY; Hwang BD; Haruna M; Imakura Y; Lee KH; Cheng YC
Mol Pharmacol; 1989 Jul; 36(1):78-82. PubMed ID: 2546053
[TBL] [Abstract][Full Text] [Related]
57. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
[TBL] [Abstract][Full Text] [Related]
58. The novel human HUEL (C4orf1) gene maps to chromosome 4p12-p13 and encodes a nuclear protein containing the nuclear receptor interaction motif.
Sim DL; Chow VT
Genomics; 1999 Jul; 59(2):224-33. PubMed ID: 10409434
[TBL] [Abstract][Full Text] [Related]
59. Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line.
Nishioka M; Kohno T; Takahashi M; Niki T; Yamada T; Sone S; Yokota J
Oncogene; 2000 Dec; 19(54):6251-60. PubMed ID: 11175339
[TBL] [Abstract][Full Text] [Related]
60. Eukaryotic DNA topoisomerase II beta.
Austin CA; Marsh KL
Bioessays; 1998 Mar; 20(3):215-26. PubMed ID: 9631649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
